Anticancer Fund
Budget
€2,457,283
EP Access
2
accredited persons
Staff
4
1.6 FTE
EU Grants
€91,654
Mission & Goals
The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value. The Anticancer Fund is a foundation of public utility with an international reach that focuses on the cure of cancer patients by: - Supporting the development of promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible. - Providing free comprehensive, evidence-based information about cancer treatments.
EU Legislative Interests
Life Science Strategy MFF Biotech Act ACT-EU Cross Border Health Care EHDS Europe’s Beating Cancer Plan Horizon: EU4Health and Missions Cancer related policies Research and clinical trials Revision of the Pharmaceutical Legislation MAC Group (Members of Parliament Against Cancer) - Intergroup
Communication Activities
1. Member of the Repurposing Observatory Group (RepOG) 2. Remedi4All was launched in September 2022: an ambitious EU-funded research initiative to drive forward the repurposing of medicines in Europe. The ACF is one of the consortium partners and has taken the lead in the organisation of the cancer path at the first international drug repurposing conference (#iDR24) that took place on 6 and 7 March 2024. We are actively involved in the preparation of iDR26. 3. Targeted EU Contact Program on cancer related policy: Webinar to raise awareness among policymakers, researchers, physicians and patients of the potential of repurposed drugs in the treatment of cancer against the backdrop of the COVID-19 pandemic. 4. Stakeholder Contact Group EBCP 5. Since 2017, the ACF was invited for STAMP meetings on the topic of drug repurposing. The ACF actively contributed to drafting the framework proposal for drug repurposing. 6. BE Presidency invitation to joint meeting NCAPR/HTA-HAG/HMA related to Drug Repurposing Keynote Speach 7. Since 2019, the ACF has been providing feedback to the commission through surveys and public consultations on Europe’s beating cancer plan, the cancer mission, the pharmaceutical strategy, Revision of EU rules on medicines for children and rare diseases and on the revision of the pharmaceutical legislation. Invitation to stakeholders dialogue. On 21 may 2021, ACF was invited to participate in the Pharmaceutical Committee on the subject of: “Future proofing of the legislation and incentives for innovation that reaches the patient”. 8. The ACF formulates its recommendations to the Mission Board and has F-2-F meetings with different MEPs. 9. Draft and publication of the Manifesto 2024-2029 10. Publication of Position Paper April 2026 on Art. 48 of draft REG
Interests Represented
Does not represent commercial interests
Member Of
https://www.icrpartnership.org/ https://www.europeancancer.org/ https://consilium-scientific.org/ (Advisory Board)
Organisation Members
https://www.anticancerfund.org/en/partners
Commissioner Meetings
No recorded meetings with EU commissioners.